About this Journal Submit a Manuscript Table of Contents
Advances in Pharmacological Sciences
Volume 2011 (2011), Article ID 572634, 13 pages
http://dx.doi.org/10.1155/2011/572634
Research Article

Oxidative Stress in Neurodegeneration

1Laboratory of Neurochemistry, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
2Molecular Genetics Unit, Laboratory of Sensory Biology, NIDCR, NIH, Bethesda, MD 20892, USA

Received 20 April 2011; Accepted 22 June 2011

Academic Editor: Donard S. Dwyer

Copyright © 2011 Varsha Shukla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

It has been demonstrated that oxidative stress has a ubiquitous role in neurodegenerative diseases. Major source of oxidative stress due to reactive oxygen species (ROS) is related to mitochondria as an endogenous source. Although there is ample evidence from tissues of patients with neurodegenerative disorders of morphological, biochemical, and molecular abnormalities in mitochondria, it is still not very clear whether the oxidative stress itself contributes to the onset of neurodegeneration or it is part of the neurodegenerative process as secondary manifestation. This paper begins with an overview of how oxidative stress occurs, discussing various oxidants and antioxidants, and role of oxidative stress in diseases in general. It highlights the role of oxidative stress in neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's diseases and amyotrophic lateral sclerosis. The last part of the paper describes the role of oxidative stress causing deregulation of cyclin-dependent kinase 5 (Cdk5) hyperactivity associated with neurodegeneration.

1. Oxidative Stress: Oxidants and Antioxidants

Oxidative stress is caused by the imbalance in the production of ROS and the biological system’s inability to detoxify those species and repair the resulting damage. The effects of oxidative stress depend upon its impact on the cellular system, whether the system is able to handle well and regain its original state or not. However, high levels of oxidative stress can cause necrosis, ATP depletion, and prevention of controlled apoptotic death [1]. In normal conditions most of the cells are maintained in a reducing environment preserved by enzymes. Any imbalance in the normal redox state leads to toxicity via production of free radicals and peroxides (constituting reactive oxygen and or nitrogen species) damaging proteins, lipids, and DNA of the cell.

ROS are of two types: less reactive and aggressive. Most of these less reactive species are produced at a low level by normal aerobic metabolism, and the damage they cause to cells is constantly repaired. However, in some instances even the less reactive species like superoxide are readily converted by oxidoreduction reactions with transition metals or other redox cycling compounds into more aggressive radical species that cause extensive cellular damage which includes damage inflicted on DNA [2]. Like in mammalian cells as a consequence of aerobic respiration within the mitochondria, superoxide is generated and sequentially reduced to hydrogen peroxide and hydroxyl radicals which confer a long-term effect on DNA by causing severe damage which ultimately leads to mutations [3].

ROS plays an important role in cell signaling, a process termed redox signaling. Thus, to maintain proper cellular homeostasis, a balance must be struck between reactive oxygen production and consumption. Excessive ROS or free radicals need to be either quenched by converting them into metabolically nondestructive molecules or be scavenged/neutralized right after their formation. This protective mechanism is called the antioxidant defense system preventing free radical mediated damage of cells leading to various diseases and aging [4].

The most common naturally occurring anti-oxidants are Vitamin A (retinol), C (ascorbic acid), and E (tocopherol), besides polyphenol antioxidants like flavonoids. Some enzymes also play an important role in combating the oxidative stress and one of the best studied is superoxide dismutase (SOD). Catalase, glutathione peroxidase, aldehyde dehydrogenases, and sulfiredoxin all belong to the class of enzymatic antioxidants [5, 6]. The use of antioxidants to prevent diseases is highly controversial as there are some studies that also suggest a secondary side affect of use of these antioxidants.

2. Oxidative Stress and Diseases

As previously mentioned the imbalance between the reactive oxygen/nitrogen species formed and quenched leads to the cell/tissue damage ultimately becoming the cause of many diseases. In humans, oxidative stress is associated with diseases in different ways. Oxidative stress could be generated as a secondary effect of a preexisting diseased condition or could be the central cause of the disease itself.

Besides being implicated in aging by the accumulation of the ROS and mutations in the mitochondrial DNA (mtDNA), oxidative stress is associated with various pathological conditions. It plays a central role in chronic lung disease (CLD) which is usually found in the preterm infants subjected to high oxygen concentration [7, 8]. High level of inflammation and infection and lower level of antioxidants in these infants lead to development of CLD. Tissue injury is also caused by oxidative stress following irradiation and hyperoxia. Both hypoxia and hyperoxia are contributors to increase in ROS. Abundant evidence has demonstrated that oxidative stress is a key player in ischemia due to oxygen reperfusion injury following hypoxia, leading to both cardiovascular diseases and strokes [9, 10]. Excessive free radicals are found in patients of chronic fatigue syndrome (CFS) [11]. Diabetes initiated due to hyperglycemia has a wide spectrum of disease manifestations as it leads to increased susceptibility of oxidative stress ultimately damaging various organs [1216]. Endothelial cell dysfunction in diabetic patients is also associated with less production of nitric oxide (NO) important in enabling relaxed state of arterial vessels. Upon administration of antioxidants like SOD and catalase, endothelial cell function is improved indicating oxidative stress as an important secondary factor in diabetes [12].

3. Oxidative Stress in Neurodegeneration

One of the most metabolically active organs of the body is the brain, including the spinal cord comprising central nervous system (CNS), which, even at rest, utilizes an estimated 20% of the total oxygen uptake. During active state this percentage substantially increases and in order to carry out normal physiological actions, it requires an uninterrupted oxygen-rich blood supply. Any blockage or deprivation of this oxygen supply even for a few seconds can have severe and irreversible detrimental effect to the cells of brain (both neurons and glia). Consumption of oxygen leads to production of free radicals and the brain requirement for higher amount of oxygen leads to even higher number of reactive oxygen/nitrogen species. Though CNS has high requirement for oxygen but unexpectedly, is relatively deficient in the enzymes that metabolize a number of oxygen-based reactants to innocuous species [17]. On the contrary, CNS is highly enriched with polyunsaturated fatty acids which are readily oxidized by toxic oxygen derivatives [18]. Additional disadvantage is the presence of the blood-brain barrier, which is designed to protect the brain from toxins by limiting their diffusion into neurons and glia but also prevents/reduces the uptake of some antioxidants like vitamin E, into the brain. These features create an additive effect making the neurons and glia highly susceptible to destruction by free radical species. Progressive loss/damage (by these radicals) of structure and function of neurons caused is called as neurodegeneration. Being the power house of the cell, mitochondria are directly associated and susceptible to oxidative stress. This is not only due to its association with ROS but also due to the fact that mitochondria is not protected with histones and is inefficiently repaired leading to high mutation rates in mitochondrial DNA (mtDNA). There has been increasing evidence suggesting that mutations acquired during ageing by mtDNA contribute to physiological decline occurring with age and age-related neurodegeneration [7]. Therefore, oxidative stress is an important factor in neurodegenerative diseases, as the damage of the neurons could be due to either an increase in oxidative process or a decrease in anti-oxidant defenses or both. Although it is extremely difficult to distinguish whether mitochondrial-derived oxidative stress is the primary cause of toxicity or just reflect the consequence of neurodegeneration, recent evidences indicate that oxidative stress is the primary event [7].

Among others the three main neurodegenerative diseases are Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) which are not only sporadic, but also have rare familial forms. These diseases occur mainly as sporadic (90%) where as the familial cause is usually limited (10%). Sporadic forms occur due to a complicated and heterogeneous mixture of hereditary, environmental factors, and lifestyle stresses. In contrast Huntington’s disease (HD), another neurodegenerative disorder is completely hereditary. HD is predominantly inherited and is strictly autosomal disorder. In the following sections role of oxidative stress in all the above-mentioned neurodegenerative disorders is briefly described.

3.1. Oxidative Stress in Alzheimer’s Disease

Clinically, Alzheimer’s disease (AD) is characterized as a late-onset, age-dependent, progressive cognitive decline which results in irreversible loss of neurons especially in the cortex and hippocampus. The major pathological hallmarks of AD are the formation of extracellular senile plaques due to amyloid beta 42 peptide (Aβ42) aggregates and the intracellular neurofilament tangles (NFT) formed by hyperphosphorylated microtubule associated protein, tau (τ) [19]. In AD, oxidative stress has been associated as one of the earlier events. Due to oxidative stress, processing of APP or τ could be altered via activation of different signaling pathway.

Usually most of the AD cases are late onset and sporadic but there are 5–10% familial AD (FAD) occurring as an early-onset and in an autosomal-dominant manner. FAD can be caused due to mutations in three genes namely, amyloid precursor protein (APP), presenilin 1, and 2 (PS1, PS2). During normal physiological conditions proteolytic cleavage of APP is initiated by α-secretase followed by γ-secretase to yield nonamyloidogenic fragments [20]. Mutations in APP causes the altered proteolytic processing replacing α-secretase by β-secretase (BACE1), followed by γ-secretase to yield amyloidogenic Aβ42 which aggregates to form insoluble plaques. Various cell culture studies have shown Aβ42 causes toxicity and induces cell death via apoptosis [21].

In contrast to senile plaques, NFTs are so far not associated with mutations but are due to modulations of kinase and phosphatase activities. Normally τ functions to regulate microtubule (MT) assembly and transport. Where as in AD τ is hyperphosphorylated and dissociates from MT, resulting in destabilizing MTs and impairment of axonal transport. The phospho-τ aggregates form the paired helical filaments (PHFs) which further combine to form the insoluble NFTs [22]. Abnormal hyperphosphorylation of tau is a reflection of both an abnormal activation of kinases, as well as decreased phosphatase activity [23]. Among various kinases, cyclin-dependent kinase 5 (Cdk5) plays a major role in causing aberrant hyperphosphorylation (discussed later in this review). Pin 1 plays an important role in post phosphorylation of proline-directed Ser/Thr-residues involved in regulating protein function. In cell culture, inhibition of Pin1 reduces oxidative stress-induced apoptosis [24]. Conformational changes catalyzed by Pin1 affect both APP and tau processing. In animal studies, Pin1 knockout mice show increase in amyloidogenic APP processing thereby increasing the levels of Aβ42 and also exhibit tau hyperphosphorylation, neuronal degeneration, motor, and behavioral deficits [25, 26].

Hyperphosphorylated τ is one of the major causes of AD pathology as it not only fails in its normal function of stabilizing microtubules, but also exhibits a “gain of toxic function” due to its sequestering normal τ. Absence of normal τ results in the disruption of microtubules [27, 28]. Hyperphosphorylated τ accumulates to form the insoluble intraneuronal PHF-τ which could reflect inhibitory binding of oxidatively damaged protein to the proteasome. Under physiological conditions any aggregate which could be a potential toxic to the system is cleaned up by the proteasome. Inhibition of this cleanup process by the proteasome is sufficient to induce neuronal degeneration and death [29]. Also, various evidences suggest that at least in some part formation of the highly insoluble NFT is associated with oxidative stress [30, 31]. For the past two decades based on various mouse models and human clinical trials, much therapeutics are being employed to fight against AD starting from the use of antioxidants, neurotrophins, and statins to the use of hormone replacement and gene therapy [32]. However, the most effective drug treatment or regimen is yet to be determined as all the current therapies either have strong side effects or are not very effective.

3.2. Oxidative Stress in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is clinically characterized by progressive weakness, atrophy, and spasticity of muscle tissue. Pathologically, ALS is an adult-onset neurodegenerative disease reflecting degeneration of upper and lower motor neurons in the cortex, brainstem, and spinal cord [33]. Like AD, ALS also occurs as both minor familial forms (fALS) and major (about 90%) sporadic forms (sALS). The major genetic defect accounting for about 3–20% of fALS is due to the mutation in the gene encoding ubiquitous enzyme Cu/Zn-superoxide dismutase (SOD-1). There have been more than 100 mutations identified in SOD-1 genes. Besides SOD-1 some of the other genes related to fALS include Alsin (ALS2), VAMP-associate protein B (VAPB), dynactin (DCTN1), TAR DNA-binding protein 43 (TDP-43), fused in sarcoma protein (FUS), and lipid phosphatase FIG4 (FIG4). Studies carried out on the postmortem tissue from sALS and fALS patients clearly show an accumulation of oxidative damage to proteins, lipids, and DNA indicating a direct role of oxidative stress in ALS [3436]. Also, ALS is multifactorial pathogenetic disease occurring due to not only oxidative stress but also excitotoxicity, aggregate formation, inflammation, growth factor deficiency, and neurofilament disorganization, making ALS a complex disease especially for its amelioration [37].

In order to better understand the ALS pathogenesis, most of the recent studies have focused on mouse models that express the mutant human SOD1 forms. These animals experience age-dependent motor neuron degeneration with cellular and biochemical damage to nerve fibers and spinal cord tissue as well as increased protein and lipid oxidation [38]. Transgenic mice overexpressing the G93ASOD1 mutation has impaired mitochondrial energy metabolism in the brain and spinal cord at the onset of the disease, also there is a transient increase in the vacuolar mitochondrial degeneration preceding motor neurons death [39, 40]. All these evidences point towards involvement of the mitochondrial abnormalities triggering the onset of ALS. Recent reports have shown evidence of localization of SOD1 to mitochondria only in affected tissues and preferentially for mutSOD1 and therefore modulate mitochondrial functions [41]. MutSOD1 may interfere with the elements of the electron transport chain (ETC) to generate toxic ROS via aberrant superoxide chemistry and to promote oxidative damage to mitochondrial proteins and lipids [42, 43]. MutSOD1 may also disrupt mechanisms by which mitochondria buffer cytosolic calcium levels.

With evidences from the mutSOD1 mouse model, the most accepted theory is that the different point mutations create a misfolding defect, leading to small amyloid-like aggregates that appear in late stages of the disease. These misfolded aggregated proteins could produce toxic effect towards neurons, similar to the neurotoxicity that arises in other amyloidoses [44, 45]. Misfolded aggregates are insoluble and are not cleared by proteasomal degradation, therefore they eventually impair and ultimately overwhelm the system [46, 47]. MutSOD1 aggregates are accumulated in the outer mitochondrial membrane and may block the protein import machines, TOM and TIM [41]. Also, mutSOD1 species bind and sequester mitochondrial Bcl-2 and cytosolic heat-shock proteins rendering them unavailable for antiapoptotic functions [48, 49].

Similar to mutSOD-1, more evidence propose alteration in proteins related to mRNA metabolism leading to protein misfolding as a salient feature of ALS pathogenesis [50, 51]. In various sALS and fALS cases, abnormal subcellular distribution and cytoplasmic aggregation of TAR DNA binding protein (TDP-43) is widely reported along with frontotemporal lobar degeneration [52, 53]. Under normal conditions, TDP-43 regulates different processes related to gene expression including transcription, splicing, and mRNA stability through RNA and DNA binding activities [50, 51, 54]. Proteomic analysis of the TDP-43 revealed associations with proteins related to RNA metabolism [55]. Also, TDP-43 interacts with components of stress granules and under oxidative stress TDP-43 redistributes itself to stress granules; however, the biological relevance of these observations is not clear yet [55, 56]. Most ALS linked mutations in TDP-43 are mapped to the C-terminal glycine-rich region, which is involved in protein–protein interactions between TDP-43 and other ribonuclear proteins [57]. In ALS and frontotemporal lobar degeneration derived tissue, C-terminal fragments of TDP-43 are specifically accumulated and have a high tendency to aggregate into intracellular inclusions [52]. Transgenic mice expressing human mutant TDP-43 develop a progressive and fatal neurodegenerative disease reminiscent of ALS, showing motor neuron loss, motor impairment, muscular atrophy, axonal degeneration, and mitochondrial dysfunction [53, 58]. Also, specific neuronal populations in the frontal cortex and the spinal cord of this mouse model show accumulation of ubiquitinated protein aggregates, suggesting that expression of TDP-43 mutants results in accumulation of misfolded proteins [53].

The above data suggests that both a toxic gain of function due to protein aggregation/mislocation together with a loss of normal biological function upon mutations contribute to disease pathogenesis. There have been mixed results of in vivo studies in the generation of ROS and oxidative damage, and trials of antioxidant therapies have been disappointing [37]. If protein misfolding is the major cause of SOD1-ALS or TDP-43 associated pathogenesis, then the drugs that could stabilize SOD1 or other proteins against misfolding would be a better therapeutic approach. Like in AD, it is unclear as to what extent potential therapeutic strategies based on the mouse models will translate to treatment of the human disease.

3.3. Oxidative Stress in Parkinson’s Disease

Parkinson’s disease (PD) is a common neurodegenerative movement disorder and is clinically characterized by progressive rigidity, bradykinesia, and tremor. Pathologically PD is characterized by loss of melanin-pigmented nigral neurons accompanied by depletion of dopamine in the striatum and the presence of Lewy bodies [59, 60]. Lewy bodies are detergent-insoluble and eosinophilic filamentous intraneuronal inclusions usually positive for ubiquitin and α-synuclein [61]. Although many evidences suggest that there is not much difference between the sporadic and the rare familial forms of PD, yet the exact molecular mechanism of the pathogenesis is still unclear. Like other neurodegenerative disorders, mitochondrial dysfunction, oxidative damage, environmental factors, and genetic predisposition may all be involved together in both sporadic as well as familial PD.

Linkage analysis has led to the discovery of pathogenic mutations or polymorphisms in mtDNA in nine genes that may account for as many as 5–10% of the cases of familial PD. Out of these genes, two are autosomal dominant (coding for α-synuclein and dardarin) and three are autosomal recessive (including parkin) [62, 63]. Other genes associated with mutations in PD include ubiquitin carboxy-terminal hydrolase L1, DJ-1, phosphatase and tensin homologue- (PTEN-) induced kinase 1 (PINK1), leucine-rich-repeat kinase 2 (LRRK2), the nuclear receptor NURR1, HTRA2, and τ [7]. These mtDNA mutations associated with PD could be large-scale rearrangements, point mutations, or microdeletions [6468]. The normal physiological function of α-synuclein is to maintain synapse and plasticity but mutations causing overexpression of α-synuclein is neurotoxic, inducing apoptosis [69, 70]. In vitro there is a strong connection between α-synuclein fibrillization and τ fibrillization and more evidence indicate frequent disease overlap between the classical tauopathies (e.g., NFT formation in AD) and synucleinopathies (e.g., Lewy body formation in PD) [7173].

Postmortem tissues from PD patients have shown evidence that a defect in complex I of the mitochondrial electron-transport chain in substantia nigra, resulting in 30–40% decrease in the activity may be the central cause of sporadic PD [74]. The decreased activity could be due to underproduction of certain complex 1 subunits, complex 1 disassembly, or self-inflected oxidative damage [7577]. More evidence of oxidative stress and PD comes from examination of substantia nigra region of human PD brain showing oxidative damage to DNA and protein along with immunocytochemical evidence for protein nitration and glycation [60, 7883]. Also the most important lipid oxidation product 4-hydroxy-2-nonenal (HNE) was modified in PD brains [84, 85]. One of the other causes of sporadic PD include point mutations in α-synuclein leading to deposition of Lewy bodies by altering posttranslational modification of α-synuclein [86]. Impaired mitochondrial function, increased oxidative stress, and enhanced nigral pathology induced by MPP+, a metabolite of MPTP (1-methyl 4-phenyl-1, 2, 3, 6-tetrahydropyridine) inhibiting complex 1 are the characteristics of the transgenic mice overexpressing α-synuclein [87]. On the contrary, α-synuclein null mice are resistant to MPTP indicating an important role in mediating toxic effects of MPTP [88].

Ubiquitin, another important protein found in Lewy bodies of sporadic PD is associated with proteolytic stress as ubiquitin-proteasome process is impaired by products of oxidative damage like HNE [59, 89]. This also relates to other genetic defects associated with familial PD; E3 ubiquitin ligase called parkin. Mitochondrial impairment and increased oxidative stress is observed in parkin-null Drosophila and mouse strains [90, 91]. Similar to mutations in parkin, mutations in DJ-1 and PINK1 are also associated with autosomal recessive juvenile PD [9295]. Both, DJ-1 and PINK1 protect against cell death. DJ-1 acts as a negative regulator of PTEN tumor-suppressor protein, increasing the cell survival and also DJ-1 null mice are hypersensitive to MPTP and oxidative stress [93]. Like DJ-1, PINK1 over expression prevents apoptosis under basal and staurospoine-induced conditions [96].

Besides mutations, overexposure to dopamine or metals like iron (Fe) and manganese (Mn) also plays an important role in the pathology of sporadic PD. In cell culture, dopamine is toxic to PC12 cell via oxidative stress, leading to apoptosis [97]. Dopamine oxidation leads to the formation of a known neurotoxin: 6-hydroxy-dopamine (6-OHDA) [98]. Two stimulants methamphetamine (METH) and 3, 4-methylenedioxymetham-phetamine (MDMA) when taken at very high dose also cause dopaminergic neurotoxicity [99]. In PD brains, a very high level of iron is found which increases with the severity of the disease [100]. High iron overload could be due to sequestration by eosinophilic protein aggregates and also iron has been implicated in the promotion of α-synuclein aggregation [101].

From the above-stated various factors causing PD, it is clear that PD not only results from a complex interplay among genetic and environmental factors, but also aspects of mitochondrial dysfunction and oxidative stress play a very important role. For a better therapeutic strategy for PD, all the causes and their interplay need to be taken into consideration for a drug, targeting PD.

3.4. Oxidative Stress in HD

As previously mentioned, Huntington’s disease (HD) is genetically inherited in an autosomal manner. Clinically HD is characterized by psychiatric disturbances, progressive cognitive impairment, and choreiform movements. Pathologically HD is characterized by loss of long projection neurons, resulting in a progressive atrophy of the caudate nucleus, putamen, and globus pallidus [102].

The HD mutation is an expansion of CAG trinucleotide repeat within exon 1 of the huntingtin (HTT) gene, a cytoplasmic protein of unknown function [103]. Because the CAG triplet codes for glutamine extension, upon mutation, the protein presents a polyglutamine tract at the N-terminus, leading to a conformational change of the protein and ultimately resulting in abnormal protein-protein interaction. In humans, adult-onset HD occurs when there are more than 40 CAG repeats, compared to the normal number which is less than 36 repeats. In juvenile cases the expansion goes up to 70 repeats or more [104]. Mutant HTT confers a dominant “gain of function” to the protein, due to expanded polyglutamine segment, ultimately leading to neurodegeneration [105]. Various lines of evidence indicate that one of the major consequences of the gene expansion may be mitochondrial metabolic defect resulting in impaired energy metabolism [106]. Impaired mitochondrial energy possibly increases more production of free radicals which in turn leads to an increased oxidative damage.

Many recent evidences from HD patients indicate involvement of mitochondrial dysfunction in the pathogenesis. HD patient brains reveal increased production of lactate in the cerebral cortex and basal ganglia upon nuclear magnetic resonance imaging spectroscopy [107, 108]. Another study reported decreased complex I activity and no change in the activities of complexes II-III and IV in platelets [109]. Biochemical studies of brain tissue from human HD brain have shown multiple defects in the caudate: decreased complex II and complex II-III activity with no alteration of complex I or IV activities [110, 111]. Also ultrastructural abnormalities in mitochondria have been described in HD cortical tissue [112, 113]. Although oxidative stress does not have a very profound effect in HD compared to other major neurodegenerative diseases, HD patients exhibit low activity of catalase in skin fibroblast cultures [114]. In studies carried out on mutant HTT-knock-in mouse embryos, significant impairment in mitochondrial respiration and ATP production was observed [115].

In summary, mutant HTT causes abnormal protein interactions affecting normal mitochondrial function leading to oxidative stress and other downstream excitotoxic and inflammatory events, together resulting in neuronal death.

4. Deregulation of Cdk5 due to Oxidative Stress Leading to Neurodegeneration

Aberrant phosphorylation caused by the deregulated activity of cyclin dependent kinase 5 (Cdk5) has been closely associated with various neurodegenerative diseases like AD, ALS, HD, and PD. Cdk5, a proline-directed serine/threonine kinase, plays multiple roles in neuron development, neuronal survival, phosphorylation of cytoskeletal proteins and synaptic plasticity [116, 117]. The active form of Cdk5 is found primarily in the nervous system due to its activator proteins p35 or p39 specifically expressed in neuronal cells [118120]. Activity of Cdk5 is tightly regulated and it plays an important role in CNS development by phosphorylating the specific serine or threonine site of numerous substrate proteins that are closely associated with the neuronal migration, synaptogenesis, and synaptic transmission as well as synaptic plasticity. However, under various stressed conditions like oxidative stress, mitochondrial dysfunctions, excitotoxicity, Aβ exposure, calcium dyshomeostasis, and inflammation lead to rise in the intracellular Ca2+. High Ca2+ concentration activates calpain which cleaves p35 to p25 forming a more stable yet hyperactive Cdk5/p25 complex [119, 121128]. Various cytoskeletal proteins are aberrantly hyperphosphorylated by this complex eventually leading to neuronal death/neurodegeneration [122, 123, 129131].

4.1. Role of Cdk5 in AD

Cdk5 is activated by oxidative stress in AD, resulting in hyperactive and aberrant Cdk5/p25 activity causing hyperphosphorylation of τ, neurofilament (NF) and other cytoskeletal proteins [123, 132, 133]. Oxidative stress and mitochondrial dysfunction are one of the earliest events in AD pathology preceding appearance of NFT [134]. Accumulation of Aβ in cortical neurons induces cleavage of p35 to p25 resulting in activation of kinases and inhibition of phosphatases proceeding NFT formation [21, 123]. Upon neuronal insult with either Aβ or glutamate, primary cortical neurons have shown enhanced Cdk5 activity. After treatment with inhibitors like roscovitine or Cdk5 inhibitory peptide (CIP), cells displayed reduction in hyperactive Cdk5 [21, 135, 136]. Also, cell culture results have shown that Aβ and glutamate toxicity cause Cdk5 to promote mitochondrial damage and induce p38 activation by increasing ROS [137, 138]. In AD brains significant increase in p25 levels and activity of Cdk5 and p38 is observed [139, 140]. Furthermore, mitochondrial depolarization results in more ROS formation and Ca2+ release, both of which eventually activate Cdk5 [122, 127]. Therefore, hyperactivity of Cdk5 is involved in promoting cell death via a feedback loop mechanism by being an upstream regulator as well as a downstream effector of mitochondrial dysfunction [137]. More evidences from cell culture studies have shown various substrates of Cdk5 leading to more ROS production. Two such substrates are peroxiredoxin-I (Prx-I) and peroxiredoxin-II (Prx-II) belonging to the Prx family of peroxidases that under physiological conditions efficiently scavenge ROS [141144]. Cdk5-mediated phosphorylation of Prx-I and Prx-II reduces their enzymatic activities resulting in ROS accumulation within the cells [137].

Silencing Cdk5 via RNA interference (RNAi) using lentiviral or adenoassociated viral vectors in the brains of transgenic AD mouse models show reduction in phosphorylation of tau and decreased number of NFTs in the hippocampus [145]. Besides being involved in hyperphosphorylation of tau and formation of NFTs, Cdk5/p25 has also been involved in phosphorylation of APP in its cytoplasmic domain at Thr668 [146]. Increased APP Thr668 phosphorylation has been observed in p25 transgenic mice compared to normal p35/Cdk5 activity [147]. These studies taken together strongly suggest that Cdk5 activation may be an early event in AD and therefore, could be used as a potential therapeutic target for AD.

4.2. Role of Cdk5 in ALS

Aberrant Cdk5 hyperactivity due to oxidative stress is also linked to motor neuron degeneration and ALS by compromising the NF dynamics [129]. In cultured neurons, when exposed to oxidative stress via treatment with hydrogen peroxide, Cdk5 phosphorylated the high molecular weight NF (NF-H). This inhibited NF axonal transport and induced perikaryal accumulation of NF phosphoepitopes normally confined to axons [148150]. Upon inhibition of Cdk5 activity with either roscovitine or CIP, these effects were prevented indicating role of Cdk5 in ALS pathology [127]. Mutations in SOD1 are associated with ALS and promote increased oxidative stress and increased production of ROS [151, 152]. Transgenic mice expressing mutant human SOD1 display increased ratio of p25/p35 in addition to abnormal localization and hyperactivation of Cdk5 [153]. Also, these mice have perturbed axonal transport and display aberrant NF accumulation within perikarya [154]. All these evidence suggests a major role of oxidative stress-induced Cdk5 hyperactivity leading to perikaryal NF phosphorylation inhibiting NF axonal transport causing motor neuron degeneration.

4.3. Role of Cdk5 in PD

Evidence of Cdk5 hyperactivity associated with PD comes from the studies involving gyrus cinguli (brain region above corpus callosum) of PD patients showing higher p25/p35 ratio due to calpain activation compared to age-matched controls [155]. As previously stated parkin phosphorylation and ubiquitination may modulate the formation of the Lewy bodies, relevant to the disease. Transgenic mouse model studies have indicated Cdk5 as a new regulator of the parkin ubiquitin-ligase activity since serine 131 has been identified as the major Cdk5 phosphorylation site in parkin. The Cdk5 phosphorylation-deficient S131A parkin mutant displays increased autoubiquitination and is more prone to aggregation upon proteasome inhibition. Furthermore, this mouse increases the formation of synphilin-1/α-synuclein inclusions indicating that phosphorylation of parkin by Cdk5 decreases its E3 ubiquitin-ligase activity and regulates the formation of cytosolic inclusions relevant to PD [156]. Phosphorylation by Cdk5 may contribute to the accumulation of toxic parkin substrates and decrease the ability of dopaminergic cells to cope with toxic insults in PD.

4.4. Role of Cdk5 in HD

Contrary to the role of Cdk5 in above-mentioned neurodegenerative diseases like AD, ALS, and PD, Cdk5 shows a neuroprotective role in HD. As mentioned earlier cause of HD is the expansion in polyQ stretch in the huntingtin (htt) protein. More than 40 polyQ tracts leads to htt protein misfolding, making it toxic and resulting in formation of aggregates and cause disease. Inhibiting polyQ aggregation alleviates the symptoms of HD patients, as reported in Drosophila and mouse models of HD [157, 158]. Short fragments of htt with expanded polyQ repeats show greater toxicity and aggregation compared with full-length mutant constructs and are sufficient to cause cell death in cell culture or disease in animal models [159, 160]. Thus, mutant htt cleavage either by caspases, calpains, or other proteases resulting in toxic fragment production may be an important rate-limiting step in HD pathogenesis [160162]. Various evidences have shown that htt not only interacts and colocalizes with Cdk5 in cellular membrane fractions but is also phosphorylated at Serine 434 leading to reduced caspase-mediated htt N-terminal cleavage at residue 513, resulting in decreased aggregation [163]. Also, Cdk5 phosphorylates at Serine1181 and Serine1201 to prevent the gain of toxic activity [164]. These results also suggest the ability of Cdk5 phosphorylation to protect against htt cleavage, aggregation and toxicity, which are compromised in cells expressing toxic fragments of htt [163]. Another study carried out on cell lines and rat or mouse cortical neuron cultures shows the kinase activity of Cdk5/p35 suppressing inclusion formation of polyQ proteins by disrupting microtubules (MTs). Cdk5-dependent regulation of MT organization is involved in the development of aggregate formation and subsequent pathogenesis of polyQ diseases [165]. This Cdk5 inhibition of htt aggregates offers a novel mechanism and hence could be used as a potential therapeutic target for HD.

Figure 1 describes in brief the role of Cdk5 in physiology as well as in pathology. Under healthy physiological conditions, Cdk5 plays a very important role in various neuronal functions. However, due to various stress and insults, deregulated Cdk5 activity leads to pathological condition.

572634.fig.001
Figure 1: Summary of role of Cdk5 in physiology and pathology. Cdk5 is a proline-directed serine/threonine kinase and gets activated by its neuron specific promoter p35. Under normal physiological (normal) conditions, Cdk5/p35 is involved with various roles in neuronal development, cognition and memory, cell adhesion, phosphorylation of cytoskeletal proteins, and synaptic plasticity. When the neurons are stressed due to various insults like oxidative stress, inflammation, mitochondrial dysfunction, or toxicity due to Aβ or glutamate, there is an increase in Ca2+ leading to activation of calpain, a protease. Calpain cleaves p35 to p25 deregulating Cdk5 activity as p25 forms a hyperactive and more stable complex with Cdk5. Cdk5/p25 activity causes aberrant phosphorylation of various proteins leading to conformational changes inducing gain of toxic function. Misfolded proteins lead to self-aggregation thereby overwhelming the system by blocking transport and disrupting synaptic activity. This ultimately leads to degeneration of neurons and finally be the cause of various neurodegenerative diseases like AD, ALS, PD, and HD.

5. Conclusions

Recent evidences have greatly increased our knowledge about the AD, ALS, PD, and HD, major neurodegenerative diseases assessed above. From various studies, it has become evident that all the neurodegenerative diseases are to some extent multifactorial, and oxidative stress is inevitably intertwined with the disease mechanisms. Besides biological factors like inflammation, excitotoxicity, and to a certain extent role of genes involved in sporadic cases, environmental contributions like diet and lifestyle are also important contributing factors for the occurrence of these diseases.

These disorders have many common factors. One such factor is the deregulation of Cdk5 as depicted in Figure 1. Cdk5 plays a very important role in these neurodegenerative disorders. In a normal physiological condition, Cdk5 along with its neuron specific activator p35 is involved in various neuronal processes necessary for normal function. Under neuronal stress and insults which could be due to many factors like oxidative stress and release of ROS, Aβ or glutamate toxicity, inflammation, and mitochondrial dysfunction, there is intracellular increase in Ca2+ concentration. This leads to the activation of proteases-like Calpain which cleaves p35 into p25. Association of p25 with Cdk5 leads to the diseased condition as Cdk5/p25 activity is deregulated causing aberrant hyperphosphorylation of various proteins like neurofilament, τ, parkin, α-synuclein, and Huntingtin. Hyperphosphorylation of these proteins leads to misfolding and aggregation causing conformational changes. Misfolded proteins self-aggregate disrupting transport and normal synaptic activity ultimately leading to neuronal degeneration and pathology.

Since oxidative stress is involved in neurodegeneration, selecting antioxidants, metal chelators, or other compounds boosting endogenous enzymatic and nonenzymatic defense mechanism seems to be an obvious choice as a treatment to these disorders. However, using antioxidants like Vitamin E (tocopherol) and others as a therapeutic target comes with a caveat as most antioxidants have metal-reducing capacity. Therefore, devising a successful regimen of antioxidants to retard the progression of these diseases remains a complicated goal. Besides using anti-oxidants as therapeutic targets, Cdk5 with all its involvement in the above mentioned neurodegenerative diseases seems to be potential and ideal candidate to be used as therapeutic target for neurodegenerative diseases.

References

  1. M. F. Beal, “Mitochondria take center stage in aging and neurodegeneration,” Annals of Neurology, vol. 58, no. 4, pp. 495–505, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. J. T. Hancock, R. Desikan, and S. J. Neill, “Role of reactive oxygen species in cell signalling pathways,” Biochemical Society Transactions, vol. 29, no. 2, pp. 345–350, 2001. View at Publisher · View at Google Scholar
  3. B. Halliwell, “Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?” Lancet, vol. 344, no. 8924, pp. 721–724, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. B. P. Yu, “Cellular defenses against damage from reactive oxygen species,” Physiological Reviews, vol. 74, no. 1, pp. 139–162, 1994. View at Scopus
  5. H. E. Poulsen, H. Prieme, and S. Loft, “Role of oxidative DNA damage in cancer initiation and promotion,” European Journal of Cancer Prevention, vol. 7, no. 1, pp. 9–16, 1998. View at Scopus
  6. B. Uday, D. Dipak, and B. K. Ranajit, “Reactive oxygen species: oxidative damage and pathogenesis,” Current Science, vol. 77, no. 5, pp. 658–666, 1999. View at Scopus
  7. M. T. Lin and M. F. Beal, “Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases,” Nature, vol. 443, no. 7113, pp. 787–795, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. O. D. Saugstad, “Chronic lung disease: the role of oxidative stress,” Biology of the Neonate, vol. 74, no. 1, pp. 21–28, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Kennedy, V. A. Spence, M. McLaren, A. Hill, C. Underwood, and J. J. F. Belch, “Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms,” Free Radical Biology and Medicine, vol. 39, no. 5, pp. 584–589, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. B. H. Trachtenberg and J. M. Hare, “Biomarkers of oxidative stress in heart failure,” Heart Failure Clinics, vol. 5, no. 4, pp. 561–577, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. Rodríguez-Yáñez and J. Castillo, “Role of inflammatory markers in brain ischemia,” Current Opinion in Neurology, vol. 21, no. 3, pp. 353–357, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. D. Giugliano, A. Ceriello, and G. Paolisso, “Oxidative stress and diabetic vascular complications,” Diabetes Care, vol. 19, no. 3, pp. 257–267, 1996. View at Scopus
  13. J. H. Kinoshita, “Aldose reductase in the diabetic eye. XLIII Edward Jackson Memorial Lecture,” American Journal of Ophthalmology, vol. 102, no. 6, pp. 685–692, 1986. View at Scopus
  14. T. J. Lyons, “Lipoprotein glycation and its metabolic consequences,” Diabetes, vol. 41, no. 2, pp. 67–73, 1992. View at Scopus
  15. A. Bowie, D. Owens, P. Collins, A. Johnson, and G. H. Tomkin, “Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?” Atherosclerosis, vol. 102, no. 1, pp. 63–67, 1993. View at Scopus
  16. J. W. Baynes, “Role of oxidative stress in development of complications in diabetes,” Diabetes, vol. 40, no. 4, pp. 405–412, 1991. View at Scopus
  17. A. Nunomura, K. Honda, A. Takeda et al., “Oxidative damage to RNA in neurodegenerative diseases,” Journal of Biomedicine and Biotechnology, vol. 2006, Article ID 82323, 6 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. G. Perry, A. Nunomura, K. Hirai et al., “Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?” Free Radical Biology and Medicine, vol. 33, no. 11, pp. 1475–1479, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. D. J. Selkoe, “Alzheimer's disease: genes, proteins, and therapy,” Physiological Reviews, vol. 81, no. 2, pp. 741–766, 2001. View at Scopus
  20. R. J. O'Brien and P. C. Wong, “Amyloid precursor protein processing and Alzheimer’s disease,” Annual Review of Neuroscience, vol. 22, no. 36, pp. 185–204, 2010.
  21. Y. L. Zheng, B. S. Li, N. D. Amin, W. Albers, and H. C. Pant, “A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells,” European Journal of Biochemistry, vol. 269, no. 18, pp. 4427–4434, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. D. P. Hanger, J. C. Betts, T. L. F. Loviny, W. P. Blackstock, and B. H. Anderton, “New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry,” Journal of Neurochemistry, vol. 71, no. 6, pp. 2465–2476, 1998. View at Scopus
  23. W. H. Stoothoff and G. V. W. Johnson, “Tau phosphorylation: physiological and pathological consequences,” Biochimica et Biophysica Acta, vol. 1739, no. 2, pp. 280–297, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. P. Rudrabhatla, Y. L. Zheng, N. D. Amin, S. Kesavapany, W. Albers, and H. C. Pant, “Pin1-dependent prolyl isomerization modulates the stress-induced phosphorylation of high molecular weight neurofilament protein,” Journal of Biological Chemistry, vol. 283, no. 39, pp. 26737–26747, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. Lim, M. Balastik, T. H. Lee et al., “Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy,” Journal of Clinical Investigation, vol. 118, no. 5, pp. 1877–1889, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. Y. C. Liou, A. Sun, A. Ryo et al., “Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration,” Nature, vol. 424, no. 6948, pp. 556–561, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. K. Iqbal, T. Zaidi, C. Bancher, and I. Grundke-Iqbal, “Alzheimer paired helical filaments. Restoration of the biological activity by dephosphorylation,” FEBS Letters, vol. 349, no. 1, pp. 104–108, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Iqbal, A. Del C. Alonso, S. Chen et al., “Tau pathology in Alzheimer disease and other tauopathies,” Biochimica et Biophysica Acta, vol. 1739, no. 2, pp. 198–210, 2005. View at Publisher · View at Google Scholar · View at PubMed
  29. S. Keck, R. Nitsch, T. Grune, and O. Ullrich, “Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease,” Journal of Neurochemistry, vol. 85, no. 1, pp. 115–122, 2003. View at Scopus
  30. P. Cras, M. A. Smith, P. L. Richey, S. L. Siedlak, P. Mulvihill, and G. Perry, “Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross linking in Alzheimer disease,” Acta Neuropathologica, vol. 89, no. 4, pp. 291–295, 1995. View at Publisher · View at Google Scholar · View at Scopus
  31. M. A. Smith, “Alzheimer disease,” International Review of Neurobiology, vol. 42, pp. 1–54, 1998. View at Scopus
  32. R. S. Shah, H.-G. Lee, Z. Xiongwei, G. Perry, M. A. Smith, and R. J. Castellani, “Current approaches in the treatment of Alzheimer's disease,” Biomedicine and Pharmacotherapy, vol. 62, no. 4, pp. 199–207, 2008. View at Publisher · View at Google Scholar · View at PubMed
  33. L. P. Rowland and N. A. Shneider, “Amyotrophic lateral sclerosis,” New England Journal of Medicine, vol. 344, no. 22, pp. 1688–1700, 2001. View at Publisher · View at Google Scholar · View at PubMed
  34. S. Kikuchi, K. Shinpo, A. Ogata et al., “Detection of Nε-(carboxymethyl)lysine (CML) and non-CML advanced glycation end-products in the anterior horn of amyotrophic lateral sclerosis spinal cord,” Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 3, no. 2, pp. 63–68, 2002.
  35. W. A. Pedersen, W. Fu, J. N. Keller et al., “Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients,” Annals of Neurology, vol. 44, no. 5, pp. 819–824, 1998.
  36. R. J. Ferrante, S. E. Browne, L. A. Shinobu et al., “Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis,” Journal of Neurochemistry, vol. 69, no. 5, pp. 2064–2074, 1997.
  37. S. C. Barber, R. J. Mead, and P. J. Shaw, “Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target,” Biochimica et Biophysica Acta, vol. 1762, no. 11-12, pp. 1051–1067, 2006. View at Publisher · View at Google Scholar · View at PubMed
  38. L. M. Sayre, G. Perry, and M. A. Smith, “Oxidative stress and neurotoxicity,” Chemical Research in Toxicology, vol. 21, no. 1, pp. 172–188, 2008. View at Publisher · View at Google Scholar · View at PubMed
  39. M. Mattiazzi, M. D'Aurelio, C. D. Gajewski et al., “Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice,” Journal of Biological Chemistry, vol. 277, no. 33, pp. 29626–29633, 2002. View at Publisher · View at Google Scholar · View at PubMed
  40. J. Kong and Z. Xu, “Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1,” Journal of Neuroscience, vol. 18, no. 9, pp. 3241–3250, 1998.
  41. J. Liu, C. Lillo, P. A. Jonsson et al., “Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria,” Neuron, vol. 43, no. 1, pp. 5–17, 2004. View at Publisher · View at Google Scholar · View at PubMed
  42. A. C. Estévez, J. P. Crow, J. B. Sampson et al., “Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase,” Science, vol. 286, no. 5449, pp. 2498–2500, 1999. View at Publisher · View at Google Scholar
  43. M. Mattiazzi, M. D'Aurelio, C. D. Gajewski et al., “Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice,” Journal of Biological Chemistry, vol. 277, no. 33, pp. 29626–29633, 2002. View at Publisher · View at Google Scholar · View at PubMed
  44. R. Rakhit and A. Chakrabartty, “Structure, folding, and misfolding of Cu,Zn superoxide dismutase in amyotrophic lateral sclerosis,” Biochimica et Biophysica Acta, vol. 1762, no. 11-12, pp. 1025–1037, 2006. View at Publisher · View at Google Scholar · View at PubMed
  45. A. Nordlund and M. Oliveberg, “Folding of Cu/Zn superoxide dismutase suggests structural hotspots for gain of neurotoxic function in ALS: parallels to precursors in amyloid disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 27, pp. 10218–10223, 2006. View at Publisher · View at Google Scholar · View at PubMed
  46. E. Kabashi and H. D. Durham, “Failure of protein quality control in amyotrophic lateral sclerosis,” Biochimica et Biophysica Acta, vol. 1762, no. 11-12, pp. 1038–1050, 2006. View at Publisher · View at Google Scholar · View at PubMed
  47. P. J. Hart, “Pathogenic superoxide dismutase structure, folding, aggregation and turnover,” Current Opinion in Chemical Biology, vol. 10, no. 2, pp. 131–138, 2006. View at Publisher · View at Google Scholar · View at PubMed
  48. A. Okado-Matsumoto and I. Fridovich, “Amyotrophic lateral sclerosis: a proposed mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 13, pp. 9010–9014, 2002. View at Publisher · View at Google Scholar · View at PubMed
  49. P. Pasinelli, M. E. Belford, N. Lennon et al., “Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria,” Neuron, vol. 43, no. 1, pp. 19–30, 2004. View at Publisher · View at Google Scholar · View at PubMed
  50. Y. Chang, Q. Kong, X. Shan et al., “Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS,” PLoS ONE, vol. 3, no. 8, Article ID e2849, 2008. View at Publisher · View at Google Scholar · View at PubMed
  51. M. J. Strong, “The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS),” Journal of the Neurological Sciences, vol. 288, no. 1-2, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at PubMed
  52. M. Neumann, D. M. Sampathu, L. K. Kwong et al., “Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis,” Science, vol. 314, no. 5796, pp. 130–133, 2006. View at Publisher · View at Google Scholar · View at PubMed
  53. I. Wegorzewska, S. Bell, N. J. Cairns, T. M. Miller, and R. H. Baloh, “TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 44, pp. 18809–18814, 2009. View at Publisher · View at Google Scholar · View at PubMed
  54. M. A. Gitcho, E. H. Bigio, M. Mishra et al., “TARDBP 3′-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy,” Acta Neuropathologica, vol. 118, no. 5, pp. 633–645, 2009. View at Publisher · View at Google Scholar · View at PubMed
  55. B. D. Freibaum, R. K. Chitta, A. A. High, and J. P. Taylor, “Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery,” Journal of Proteome Research, vol. 9, no. 2, pp. 1104–1120, 2010. View at Publisher · View at Google Scholar · View at PubMed
  56. C. Colombrita, E. Zennaro, C. Fallini et al., “TDP-43 is recruited to stress granules in conditions of oxidative insult,” Journal of Neurochemistry, vol. 111, no. 4, pp. 1051–1061, 2009. View at Publisher · View at Google Scholar · View at PubMed
  57. C. Lagier-Tourenne and D. W. Cleveland, “Rethinking ALS: the FUS about TDP-43,” Cell, vol. 136, no. 6, pp. 1001–1004, 2009. View at Publisher · View at Google Scholar · View at PubMed
  58. Y. F. Xu, T. F. Gendron, Y. J. Zhang et al., “Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice,” Journal of Neuroscience, vol. 30, no. 32, pp. 10851–10859, 2010. View at Publisher · View at Google Scholar · View at PubMed
  59. P. Jenner, Hunot, Olanow et al., “Oxidative stress in Parkinson's disease,” Annals of Neurology, vol. 53, no. 3, pp. S26–S38, 2003. View at Publisher · View at Google Scholar · View at PubMed
  60. A. Kikuchi, A. Takeda, H. Onodera et al., “Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy,” Neurobiology of Disease, vol. 9, no. 2, pp. 244–248, 2002. View at Publisher · View at Google Scholar · View at PubMed
  61. P. G. Galloway, P. Mulvihill, and G. Perry, “Filaments of Lewy bodies contain insoluble cytoskeletal elements,” American Journal of Pathology, vol. 140, no. 4, pp. 809–822, 1992.
  62. N. Hattori and P. Y. Mizuno, “Pathogenetic mechanisms of parkin in Parkinson's disease,” Lancet, vol. 364, no. 9435, pp. 722–724, 2004. View at Publisher · View at Google Scholar · View at PubMed
  63. A. Wood-Kaczmar, S. Gandhi, and N. W. Wood, “Understanding the molecular causes of Parkinson's disease,” Trends in Molecular Medicine, vol. 12, no. 11, pp. 521–528, 2006. View at Publisher · View at Google Scholar · View at PubMed
  64. R. Castellani, K. Hirai, G. Aliev et al., “Role of mitochondrial dysfunction in Alzheimer's disease,” Journal of Neuroscience Research, vol. 70, no. 3, pp. 357–360, 2002. View at Publisher · View at Google Scholar · View at PubMed
  65. R. M. Chalmers, M. Brockington, R. S. Howard, B. R. F. Lecky, J. A. Morgan-Hughes, and A. E. Harding, “Mitochondrial encephalopathy with multiple mitochondrial DNA deletions: a report of two families and two sporadic cases with unusual clinical and neuropathological features,” Journal of the Neurological Sciences, vol. 143, no. 1-2, pp. 41–45, 1996. View at Publisher · View at Google Scholar
  66. G. Siciliano, M. Mancuso, R. Ceravolo, V. Lombardi, A. Iudice, and U. Bonuccelli, “Mitochondrial DNA rearrangements in young onset parkinsonismml: two case reports,” Journal of Neurology Neurosurgery and Psychiatry, vol. 71, no. 5, pp. 685–687, 2001. View at Publisher · View at Google Scholar
  67. I. F. M. De Coo, W. O. Renier, W. Ruitenbeek et al., “A 4-base pair deletion in the mitochondrial cytochrome b gene associated with Parkinsonism/MELAS overlap syndrome,” Annals of Neurology, vol. 45, no. 1, pp. 130–133, 1999. View at Publisher · View at Google Scholar
  68. D. Thyagarajan, S. Bressman, C. Bruno et al., “A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy,” Annals of Neurology, vol. 48, no. 5, pp. 730–736, 2000. View at Publisher · View at Google Scholar
  69. W. Zhou, M. S. Huribert, J. Schaack, K. N. Prasad, and C. R. Freed, “Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells,” Brain Research, vol. 866, no. 1-2, pp. 33–43, 2000. View at Publisher · View at Google Scholar
  70. M. Lee, D. H. Hyun, B. Halliwell, and P. Jenner, “Effect of the overexpression of wild-type or mutant α-synuclein on cell susceptibility to insult,” Journal of Neurochemistry, vol. 76, no. 4, pp. 998–1009, 2001. View at Publisher · View at Google Scholar
  71. B. I. Giasson, M. S. Forman, M. Higuchi et al., “Initiation and synergistic fibrillization of tau and alpha-synuctein,” Science, vol. 300, no. 5619, pp. 636–640, 2003. View at Publisher · View at Google Scholar · View at PubMed
  72. E. Iseki, W. Marui, K. Kosaka, and K. Uéda, “Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease,” Neuroscience Letters, vol. 265, no. 1, pp. 9–12, 1999. View at Publisher · View at Google Scholar
  73. V. M. Y. Lee, B. I. Giasson, and J. Q. Trojanowski, “More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases,” Trends in Neurosciences, vol. 27, no. 3, pp. 129–134, 2004. View at Publisher · View at Google Scholar · View at PubMed
  74. T. M. Dawson and V. L. Dawson, “Molecular pathways of neurodegeneration in Parkinson's disease,” Science, vol. 302, no. 5646, pp. 819–822, 2003. View at Publisher · View at Google Scholar · View at PubMed
  75. A. H. Schapira, “Causes of neuronal death in Parkinson's disease,” Advances in neurology, vol. 86, pp. 155–162, 2001.
  76. M. F. Beal, “Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment,” Journal of Bioenergetics and Biomembranes, vol. 36, no. 4, pp. 381–386, 2004. View at Publisher · View at Google Scholar · View at PubMed
  77. P. M. Keeney, J. Xie, R. A. Capaldi, and J. P. Bennett Jr., “Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled,” Journal of Neuroscience, vol. 26, no. 19, pp. 5256–5264, 2006. View at Publisher · View at Google Scholar · View at PubMed
  78. J. Sanchez-Ramos, E. Overvik, and B. Ames, “A marker of oxyradical-mediated DNA damage (8-hydroxy-2-deoxyguanosine) is increased in nigro-striatum of Parkinson’s disease brain,” Neurodegeneration, vol. 3, pp. 197–204, 1994.
  79. J. Zhang, G. Perry, M. A. Smith et al., “Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons,” American Journal of Pathology, vol. 154, no. 5, pp. 1423–1429, 1999.
  80. Z. I. Alam, S. E. Daniel, A. J. Lees, D. C. Marsden, P. Jenner, and B. Halliwell, “A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease,” Journal of Neurochemistry, vol. 69, no. 3, pp. 1326–1329, 1997.
  81. E. Floor and M. G. Wetzel, “Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay,” Journal of Neurochemistry, vol. 70, no. 1, pp. 268–275, 1998.
  82. P. F. Good, A. Hsu, P. Werner, D. P. Perl, and C. Warren Olanow, “Protein nitration in Parkinson's disease,” Journal of Neuropathology and Experimental Neurology, vol. 57, no. 4, pp. 338–342, 1998.
  83. R. Castellani, M. A. Smith, P. L. Richey, and G. Perry, “Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease,” Brain Research, vol. 737, no. 1-2, pp. 195–200, 1996. View at Publisher · View at Google Scholar
  84. A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E. R. Stadtman, and Y. Mizuno, “Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 7, pp. 2696–2701, 1996. View at Publisher · View at Google Scholar
  85. R. J. Castellani, G. Perry, S. L. Siedlak et al., “Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans,” Neuroscience Letters, vol. 319, no. 1, pp. 25–28, 2002. View at Publisher · View at Google Scholar
  86. R. A. Fredenburg, C. Rospigliosi, R. K. Meray et al., “The impact of the E46K mutation on the properties of α-synuclein in its monomelic and oligomeric states,” Biochemistry, vol. 46, no. 24, pp. 7107–7118, 2007. View at Publisher · View at Google Scholar · View at PubMed
  87. D. D. Song, C. W. Shults, A. Sisk, E. Rockenstein, and E. Masliah, “Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP,” Experimental Neurology, vol. 186, no. 2, pp. 158–172, 2004. View at Publisher · View at Google Scholar · View at PubMed
  88. P. Klivenyi, D. Siwek, G. Gardian et al., “Mice lacking alpha-synuclein are resistant to mitochondrial toxins,” Neurobiology of Disease, vol. 21, no. 3, pp. 541–548, 2006. View at Publisher · View at Google Scholar · View at PubMed
  89. K. S. P. McNaught, R. Belizaire, O. Isacson, P. Jenner, and C. W. Olanow, “Altered proteasomal function in sporadic Parkinson's disease,” Experimental Neurology, vol. 179, no. 1, pp. 38–46, 2003. View at Publisher · View at Google Scholar
  90. Y. Pesah, T. Pham, H. Burgess et al., “Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress,” Development, vol. 131, no. 9, pp. 2183–2194, 2004. View at Publisher · View at Google Scholar · View at PubMed
  91. J. J. Palacino, D. Sagi, M. S. Goldberg et al., “Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice,” Journal of Biological Chemistry, vol. 279, no. 18, pp. 18614–18622, 2004. View at Publisher · View at Google Scholar · View at PubMed
  92. V. Bonifati, P. Rizzu, M. J. Van Baren et al., “Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism,” Science, vol. 299, no. 5604, pp. 256–259, 2003. View at Publisher · View at Google Scholar · View at PubMed
  93. R. H. Kim, P. D. Smith, H. Aleyasin et al., “Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrindine (MPTP) and oxidative stress,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 14, pp. 5215–5220, 2005. View at Publisher · View at Google Scholar · View at PubMed
  94. M. C. Meulener, K. Xu, L. Thompson, H. Ischiropoulos, and N. M. Bonini, “Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12517–12522, 2006. View at Publisher · View at Google Scholar · View at PubMed
  95. E. M. Valente, P. M. Abou-Sleiman, V. Caputo et al., “Hereditary early-onset Parkinson's disease caused by mutations in PINK1,” Science, vol. 304, no. 5674, pp. 1158–1160, 2004. View at Publisher · View at Google Scholar · View at PubMed
  96. A. Petit, T. Kawarai, E. Paitel et al., “Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations,” Journal of Biological Chemistry, vol. 280, no. 40, pp. 34025–34032, 2005. View at Publisher · View at Google Scholar · View at PubMed
  97. D. C. Jones, P. G. Gunasekar, J. L. Borowitz, and G. E. Isom, “Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells,” Journal of Neurochemistry, vol. 74, no. 6, pp. 2296–2304, 2000. View at Publisher · View at Google Scholar
  98. A. Napolitano, O. Crescenzi, A. Pezzella, and G. Prota, “Generation of the neurotoxin 6-hydroxydopamine by peroxidase/H2O2 oxidation of dopamine,” Journal of Medicinal Chemistry, vol. 38, no. 6, pp. 917–922, 1995.
  99. S. Z. Imam, J. El-Yazal, G. D. Newport et al., “Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts,” Annals of the New York Academy of Sciences, vol. 939, pp. 366–380, 2001.
  100. M. E. Götz, K. Double, M. Gerlach, M. B. H. Youdim, and P. Riederer, “The relevance of iron in the pathogenesis of Parkinson's disease,” Annals of the New York Academy of Sciences, vol. 1012, pp. 193–208, 2004. View at Publisher · View at Google Scholar
  101. D. Kaur and J. Andersen, “Does cellular iron dysregulation play a causative role in Parkinson's disease?” Ageing Research Reviews, vol. 3, no. 3, pp. 327–343, 2004. View at Publisher · View at Google Scholar · View at PubMed
  102. S. Davies and D. B. Ramsden, “Huntington's disease,” Journal of Clinical Pathology, vol. 54, no. 6, pp. 409–413, 2001.
  103. J. F. Gusella, N. S. Wexler, and P. M. Conneally, “A polymorphic DNA marker genetically linked to Huntington's disease,” Nature, vol. 306, no. 5940, pp. 234–238, 1983.
  104. A. C. Rego and C. R. Oliveira, “Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases,” Neurochemical Research, vol. 28, no. 10, pp. 1563–1574, 2003. View at Publisher · View at Google Scholar
  105. J. F. Gusella and M. E. McDonald, “Huntington’s disease,” Seminars in Cell Biology, vol. 6, pp. 21–28, 1995.
  106. S. E. Browne, A. C. Bowling, U. MacGarvey et al., “Oxidative damage and metabolic dysfunction in huntington's disease: selective vulnerability of the basal ganglia,” Annals of Neurology, vol. 41, no. 5, pp. 646–653, 1997. View at Publisher · View at Google Scholar · View at PubMed
  107. B. G. Jenkins, W. J. Koroshetz, M. F. Beal, and B. R. Rosen, “Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy,” Neurology, vol. 43, no. 12 I, pp. 2689–2695, 1993.
  108. W. J. Koroshetz, B. G. Jenkins, B. R. Rosen, and M. Flint Beal, “Energy metabolism defects in Huntington's disease and effects of coenzyme Q10,” Annals of Neurology, vol. 41, no. 2, pp. 160–165, 1997. View at Publisher · View at Google Scholar · View at PubMed
  109. W. D. Parker, S. J. Boyson, A. S. Luder, and J. K. Parks, “Evidence for a defect in NADH:ubiquinone oxidoreductase (complex I) in Huntington's disease,” Neurology, vol. 40, no. 8, pp. 1231–1234, 1990.
  110. J. Butterworth, C. M. Yates, and G. P. Reynolds, “Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and γ-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases,” Journal of the Neurological Sciences, vol. 67, no. 2, pp. 161–171, 1985. View at Publisher · View at Google Scholar
  111. V. M. Mann, J. M. Cooper, F. Javoy-Agid, Y. Agid, P. Jenner, and A. H.V. Schapira, “Mitochondrial function and parental sex effect in Huntington's disease,” Lancet, vol. 336, no. 8717, p. 749, 1990.
  112. H. H. Goebel, R. Heipertz, and W. Scholz, “Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies,” Neurology, vol. 28, no. 1, pp. 23–31, 1978.
  113. G. Gárdián and L. Vécsei, “Huntington's disease: pathomechanism and therapeutic perspectives,” Journal of Neural Transmission, vol. 111, no. 10-11, pp. 1485–1494, 2004. View at Publisher · View at Google Scholar · View at PubMed
  114. P. Del Hoyo, A. García-Redondo, F. De Bustos et al., “Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease,” Neurochemical Research, vol. 31, no. 9, pp. 1103–1109, 2006. View at Publisher · View at Google Scholar · View at PubMed
  115. T. Milakovic and G. V. W. Johnson, “Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin,” Journal of Biological Chemistry, vol. 280, no. 35, pp. 30773–30782, 2005. View at Publisher · View at Google Scholar · View at PubMed
  116. B.-S. Li, L. Zhang, J. Gu, N. D. Amin, and H. C. Pant, “Integrin α1β1-mediated activation of cyclin-dependent kinase 5 activity is involved in neurite outgrowth and human neurofilament protein H Lys-Ser-Pro tail domain phosphorylation,” Journal of Neuroscience, vol. 20, no. 16, pp. 6055–6062, 2000.
  117. D. S. Smith and L. H. Tsai, “Cdk5 behind the wheel: a role in trafficking and transport?” Trends in Cell Biology, vol. 12, no. 1, pp. 28–36, 2002. View at Publisher · View at Google Scholar
  118. M. S. Lee, Y. T. Kwon, M. Li, J. Peng, R. M. Friedlander, and L. H. Tsai, “Neurotoxicity induces cleavage of p35 to p25 by calpain,” Nature, vol. 405, no. 6784, pp. 360–364, 2000. View at Publisher · View at Google Scholar · View at PubMed
  119. R. Dhavan and L. H. Tsai, “A decade of CDK5,” Nature Reviews Molecular Cell Biology, vol. 2, no. 10, pp. 749–759, 2001. View at Publisher · View at Google Scholar · View at PubMed
  120. N. D. Amin, W. Albers, and H. C. Pant, “Cyclin-dependent kinase 5 (cdk5) activation requires interaction with three domains of p35,” Journal of Neuroscience Research, vol. 67, no. 3, pp. 354–362, 2002. View at Publisher · View at Google Scholar · View at PubMed
  121. L. H. Tsai, I. Delalle, V. S. Caviness, T. Chae, and E. Harlow, “p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5,” Nature, vol. 371, no. 6496, pp. 419–423, 1994. View at Publisher · View at Google Scholar · View at PubMed
  122. G. N. Patrick, L. Zukerberg, M. Nikolic, S. De La Monte, P. Dikkes, and L. H. Tsai, “Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration,” Nature, vol. 402, no. 6762, pp. 615–622, 1999. View at Publisher · View at Google Scholar · View at PubMed
  123. M. S. Lee, Y. T. Kwon, M. Li, J. Peng, R. M. Friedlander, and L. H. Tsai, “Neurotoxicity induces cleavage of p35 to p25 by calpain,” Nature, vol. 405, no. 6784, pp. 360–364, 2000. View at Publisher · View at Google Scholar · View at PubMed
  124. P. Strocchi, A. Pession, and B. Dozza, “Up-regulation of cDK5/p35 by oxidative stress in human neuroblastoma IMR-32 cells,” Journal of Cellular Biochemistry, vol. 88, no. 4, pp. 758–765, 2003. View at Publisher · View at Google Scholar · View at PubMed
  125. J. C. Cruz and L. H. Tsai, “Cdk5 deregulation in the pathogenesis of Alzheimer's disease,” Trends in Molecular Medicine, vol. 10, no. 9, pp. 452–458, 2004. View at Publisher · View at Google Scholar · View at PubMed
  126. R. A. Quintanilla, D. I. Orellana, C. González-Billault, and R. B. Maccioni, “Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway,” Experimental Cell Research, vol. 295, no. 1, pp. 245–257, 2004. View at Publisher · View at Google Scholar · View at PubMed
  127. T. B. Shea, Y. L. Zheng, D. Ortiz, and H. C. Pant, “Cyclin-dependent kinase 5 increases perikaryal neurofilament phosphorylation and inhibits neurofilament axonal transport in response to oxidative stress,” Journal of Neuroscience Research, vol. 76, no. 6, pp. 795–800, 2004. View at Publisher · View at Google Scholar · View at PubMed
  128. M. Kitazawa, S. Oddo, T. R. Yamasaki, K. N. Green, and F. M. LaFerla, “Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease,” Journal of Neuroscience, vol. 25, no. 39, pp. 8843–8853, 2005. View at Publisher · View at Google Scholar · View at PubMed
  129. H. Patzke and L. H. Tsai, “Cdk5 sinks into ALS,” Trends in Neurosciences, vol. 25, no. 1, pp. 8–10, 2002. View at Publisher · View at Google Scholar
  130. H. C. Tseng, Y. Zhou, Y. Shen, and L. H. Tsai, “A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains,” FEBS Letters, vol. 523, no. 1–3, pp. 58–62, 2002. View at Publisher · View at Google Scholar
  131. M. S. Lee and L. H. Tsai, “Cdk5: one of the links between senile plaques and neurofibrillary tangles?” Journal of Alzheimer's Disease, vol. 5, no. 2, pp. 127–137, 2003.
  132. S. M. De La Monte, N. Ganju, N. Feroz et al., “Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells,” Journal of Alzheimer's Disease, vol. 2, no. 3-4, pp. 261–281, 2000.
  133. M. Hashiguchi, T. Saito, S.-I. Hisanaga, and T. Hashiguchi, “Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau,” Journal of Biological Chemistry, vol. 277, no. 46, pp. 44525–44530, 2002. View at Publisher · View at Google Scholar · View at PubMed
  134. A. Nunomura, G. Perry, G. Aliev et al., “Oxidative damage is the earliest event in Alzheimer disease,” Journal of Neuropathology and Experimental Neurology, vol. 60, no. 8, pp. 759–767, 2001.
  135. S. Kesavapany, Y. L. Zheng, N. Amin, and H. C. Pant, “Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5,” Biotechnology Journal, vol. 2, no. 8, pp. 978–987, 2007. View at Publisher · View at Google Scholar · View at PubMed
  136. Y. L. Zheng, S. Kesavapany, M. Gravell et al., “A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons,” EMBO Journal, vol. 24, no. 1, pp. 209–220, 2005. View at Publisher · View at Google Scholar · View at PubMed
  137. K. H. Sun, Y. De Pablo, F. Vincent, and K. Shah, “Deregulated Cdk5 promotes oxidative stress and mitochondrial dysfunction,” Journal of Neurochemistry, vol. 107, no. 1, pp. 265–278, 2008. View at Publisher · View at Google Scholar · View at PubMed
  138. K. H. Chang, Y. De Pablo, H. P. Lee, H. G. Lee, M. A. Smith, and K. Shah, “Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease,” Journal of Neurochemistry, vol. 113, no. 5, pp. 1221–1229, 2010. View at Publisher · View at Google Scholar · View at PubMed
  139. J. J. Pei, E. Braak, H. Braak et al., “Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration,” Journal of Alzheimer's Disease, vol. 3, no. 1, pp. 41–48, 2001.
  140. X. Zhu, C. A. Rottkamp, A. Hartzler et al., “Activation of MKK6, an upstream activator of p38, in Alzheimer's disease,” Journal of Neurochemistry, vol. 79, no. 2, pp. 311–318, 2001. View at Publisher · View at Google Scholar
  141. H. Mizusawa, T. Ishii, and S. Bannai, “Peroxiredoxin I (macrophage 23 kDa stress protein) is highly and widely expressed in the rat nervous system,” Neuroscience Letters, vol. 283, no. 1, pp. 57–60, 2000. View at Publisher · View at Google Scholar
  142. T. S. Chang, W. Jeong, S. Y. Choi, S. Yu, S. W. Kang, and S. G. Rhee, “Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation,” Journal of Biological Chemistry, vol. 277, no. 28, pp. 25370–25376, 2002. View at Publisher · View at Google Scholar · View at PubMed
  143. S. W. Kang, S. G. Rhee, T. S. Chang, W. Jeong, and M. H. Choi, “2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications,” Trends in Molecular Medicine, vol. 11, no. 12, pp. 571–578, 2005. View at Publisher · View at Google Scholar · View at PubMed
  144. E. A. Veal, A. M. Day, and B. A. Morgan, “Hydrogen peroxide sensing and signaling,” Molecular Cell, vol. 26, no. 1, pp. 1–14, 2007. View at Publisher · View at Google Scholar · View at PubMed
  145. D. Piedrahita, I. Hernández, A. López-Tobón et al., “Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer's mice,” Journal of Neuroscience, vol. 30, no. 42, pp. 13966–13976, 2010. View at Publisher · View at Google Scholar · View at PubMed
  146. K.-I. Iijima, K. Ando, S. Takeda et al., “Neuron-specific phosphorylation of Alzheimer's β-amyloid precursor protein by cyclin-dependent kinase 5,” Journal of Neurochemistry, vol. 75, no. 3, pp. 1085–1091, 2000. View at Publisher · View at Google Scholar
  147. J. C. Cruz, H. C. Tseng, J. A. Goldman, H. Shih, and L. H. Tsai, “Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles,” Neuron, vol. 40, no. 3, pp. 471–483, 2003. View at Publisher · View at Google Scholar
  148. A. C. Pant, Veeranna, H. C. Pant, and N. Amin, “Phosphorylation of human high molecular weight neurofilament protein (hNF-H) by neuronal cyclin-dependent kinase 5 (cdk5),” Brain Research, vol. 765, no. 2, pp. 259–266, 1997. View at Publisher · View at Google Scholar
  149. M. Sharma, P. Sharma, and H. C. Pant, “CDK-5-mediated neurofilament phosphorylation in SHSY5Y human neuroblastoma cells,” Journal of Neurochemistry, vol. 73, no. 1, pp. 79–86, 1999. View at Publisher · View at Google Scholar
  150. P. Grant, P. Sharma, and H. C. Pant, “Cyclin-dependent protein kinase 5 (Cdk5) and the regulation of neurofilament metabolism,” European Journal of Biochemistry, vol. 268, no. 6, pp. 1534–1546, 2001. View at Publisher · View at Google Scholar
  151. M. R. Cookson and P. J. Shaw, “Oxidative stress and motor neurone disease,” Brain Pathology, vol. 9, no. 1, pp. 165–186, 1999.
  152. M. Strong, “The basics of therapeutics in amyotrophic lateral sclerosis,” Pharmacology & Therapeutics, vol. 5542, pp. 1–36, 2003.
  153. M. D. Nguyen, R. C. Larivière, and J. P. Julien, “Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions,” Neuron, vol. 30, no. 1, pp. 135–147, 2001. View at Publisher · View at Google Scholar
  154. M. V. Rao and R. A. Nixon, “Defective neurofilament transport in mouse models of amyotrophic lateral sclerosis: a review,” Neurochemical Research, vol. 28, no. 7, pp. 1041–1047, 2003. View at Publisher · View at Google Scholar
  155. D. Alvira, I. Ferrer, J. Gutierrez-Cuesta, B. Garcia-Castro, M. Pallàs, and A. Camins, “Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 14, no. 4, pp. 309–313, 2008. View at Publisher · View at Google Scholar · View at PubMed
  156. E. Avraham, R. Rott, E. Liani, R. Szargel, and S. Engelender, “Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation,” Journal of Biological Chemistry, vol. 282, no. 17, pp. 12842–12850, 2007. View at Publisher · View at Google Scholar · View at PubMed
  157. A. Kazantsev, H. A. Walker, N. Slepko et al., “A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila,” Nature Genetics, vol. 30, no. 4, pp. 367–376, 2002. View at Publisher · View at Google Scholar · View at PubMed
  158. I. Sánchez, C. Mahlke, and J. Yuan, “Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders,” Nature, vol. 421, no. 6921, pp. 373–379, 2003. View at Publisher · View at Google Scholar · View at PubMed
  159. Y. P. Goldberg, D. W. Nicholson, D. M. Rasper et al., “Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract,” Nature Genetics, vol. 13, no. 4, pp. 442–449, 1996. View at Publisher · View at Google Scholar · View at PubMed
  160. C. L. Wellington, R. Singaraja, L. Ellerby et al., “Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells,” Journal of Biological Chemistry, vol. 275, no. 26, pp. 19831–19838, 2000. View at Publisher · View at Google Scholar · View at PubMed
  161. Y. J. Kim, Y. Yi, E. Sapp et al., “Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpaindependent proteolysis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 22, pp. 12784–12789, 2001. View at Publisher · View at Google Scholar · View at PubMed
  162. A. Lunkes, K. S. Lindenberg, L. Ben-Haem et al., “Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions,” Molecular Cell, vol. 10, no. 2, pp. 259–269, 2002. View at Publisher · View at Google Scholar
  163. S. Luo, C. Vacher, J. E. Davies, and D. C. Rubinsztein, “Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity,” Journal of Cell Biology, vol. 169, no. 4, pp. 647–656, 2005. View at Publisher · View at Google Scholar · View at PubMed
  164. S. L. Anne, F. Saudou, and S. Humbert, “Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons,” Journal of Neuroscience, vol. 27, no. 27, pp. 7318–7328, 2007. View at Publisher · View at Google Scholar · View at PubMed
  165. S. Kaminosono, T. Saito, F. Oyama et al., “Suppression of mutant huntingtin aggregate formation by Cdk5/p35 through the effect on microtubule stability,” Journal of Neuroscience, vol. 28, no. 35, pp. 8747–8755, 2008. View at Publisher · View at Google Scholar · View at PubMed